Collaboration Needed To Ensure Access To Orphan Drugs – Express Scripts Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
In an effort to ensure that there is access to high-priced drugs that treat rare diseases, relevant stakeholders, including manufacturers, payers, patients and physicians, need to come together and collaborate on access solutions that meet the needs of all parties, Express Scripts VP of Pharma Strategies and Account Management Bill Martin tells NORD/DIA conference.
You may also be interested in...
Rare Disease Drugs Deserve Lower Cost Sharing In Part D, McClellan Says
In a speech to an Oct. 24 conference on rare diseases and orphan drugs, former CMS Administrator Mark McClellan said drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies, which typically require coinsurance of 25% to 33%.
Pricing Rare Disease Drugs Requires Care As Payers Increase Scrutiny
Value questions are expected to be asked by payers and others as larger pharma companies enter the orphan drug space and more treatments debut targeting rare diseases.
Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year
Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement